

Neuroendocrine Tumors

[View the current Neuroendocrine Tumors InDepth page on BioPortfolio.com \(PDF\)](#)
(http://www.bioportfolio.com/indepth/Neuroendocrine_Tumors.html) - Regularly Updated.

Recent Publications on Neuroendocrine Tumors:



- [Gastroenteropancreatic neuroendocrine tumors: 10-year experience in a single center.](#)
*Neuroendocrine tumors originate from neuroendocrine cells and occur in a...*13th November, 2009
Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul- Med Oncol. 2009 Nov 3. ([DOI Direct Link](#))
- [Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors.](#)
*Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are rare neoplasms...*10th November, 2009
Department of Medical Oncology, Vall d'Hebron University Hospital,- Target Oncol. 2009 Nov 7. ([DOI Direct Link](#))
- [The utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for assessment of lung lesions in patients with neuroendocrine tumors.](#)
*Our aim was to assess clinical utility of 99mTc-EDDA/HYNIC-TOC...*10th November, 2009
- Neoplasma. 2010;57(1):68-73.
- [Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies.](#)
*Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits...*10th November, 2009
Oncology Unit, Third Department of Medicine, Athens University School of- BioDrugs. 2009;23(6):377-89. doi: 10.2165/11318860-000000000-00000. ([DOI Direct Link](#))
- [Pancreatic neuroendocrine tumors: presentation, management, and outcomes.](#)
*Pancreatic neuroendocrine tumors (pNETs) are an uncommon pancreatic...*5th November, 2009
Department of Surgery, Center for Liver Diseases and Transplantation,- Am Surg. 2009 Oct;75(10):1025-9.
- [High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience.](#)
*INTRODUCTION: High-administered activity In-111 octreotide (HA-Oc) therapy...*3rd November, 2009
Center for Molecular Imaging, Peter MacCallum Cancer Center, East- Cancer Biother Radiopharm. 2009 Oct;24(5):527-33. ([DOI Direct Link](#))
- [Radioiodinated metaiodobenzylguanidine treatment of neuroendocrine tumors in adults.](#)
*Metaiodobenzylguanidine (MIBG), radioiodinated with (131)I, has been...*3rd November, 2009
Department of Oncologic Imaging, Cross Cancer Institute, Edmonton,- Cancer Biother Radiopharm. 2009 Oct;24(5):519-25. ([DOI Direct Link](#))
- [Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.](#)
*ABSTRACT: The mammalian target of rapamycin (mTOR) is an intracellular...*29th October, 2009
Novartis- J Hematol Oncol. 2009 Oct 27;2:45. ([DOI Direct Link](#))

- [Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas.](#)
AIM: To assess the patient-reported outcomes (PROs) of pancreatic...28th October, 2009
Department of Digestive Diseases and Internal Medicine,- World J Gastroenterol. 2009 Oct 28;15(40):5067-73.
- [Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes.](#)
AIMS AND BACKGROUND: Carcinoids are infrequent neoplasms arising from...28th October, 2009
Unit of Medical Oncology2, Centro di Riferimento per lo Studio e la Cura- Tumori. 2009 Jul-Aug;95(4):501-7.
- [Twenty-Five-Year Follow-up for Liver Resection: The Personal Series of Dr. Joseph G. Fortner.](#)
BACKGROUND:: Liver resection is performed for many types of malignancies...27th October, 2009
From the Memorial Sloan-Kettering Cancer Center, New York, NY.- Ann Surg. 2009 Oct 21. ([DOI Direct Link](#))
- [Biochemical testing for neuroendocrine tumors.](#)
In this review, we focus on the use of biochemical markers for the...27th October, 2009
Eastern Virginia Medical School, Strelitz Diabetes Research Center,- Pancreas. 2009 Nov;38(8):876-89. ([DOI Direct Link](#))
- [Synthesis, characterization and in vitro evaluation of new oxorhenium- and oxotechnetium-CCK4 derivatives as molecular imaging agents for CCK2-receptor targeting.](#)
The goal of this study is to design new (99m)Tc-radiolabelled shortened...27th October, 2009
CNRS; Laboratoire de Synthèse et Physico-Chimie de Molécules d'Intéret- Eur J Med Chem. 2009 Oct 8. ([DOI Direct Link](#))
- [High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.](#)
BACKGROUND: Long-acting sandostatin (S-LAR; octreotide acetate) is well...23rd October, 2009
Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton- Anticancer Res. 2009 Oct;29(10):4127-30.

BioNews Results for Neuroendocrine Tumors

- [Biochemical Testing for Neuroendocrine Tumors](#)
MDLinx: Oct 23 2009 11:13AM Matching: neuroendocrine tumors
- [Liver Metastases of Neuroendocrine Tumors: Treatment With Hepatic Transarterial Chemotherapy Using Two Therapeutic Protocols](#)
MDLinx: Oct 8 2009 12:29PM Matching: neuroendocrine tumors
- [Molecular Insight Pharmaceuticals Presents Azedra Efficacy Data in Neuroendocrine Tumors](#)
Pharma Live: Oct 6 2009 2:39AM Matching: neuroendocrine tumors
- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical Trial in Neuroendocrine Tumors](#)
Individual.com: Oct 5 2009 12:49PM Matching: neuroendocrine tumors
- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical Trial In Neur](#)
Medical News Today: Oct 6 2009 10:11AM Matching: neuroendocrine tumors
- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical Trial in Ne](#)
Pharmacy Choice: Oct 5 2009 9:59PM Matching: neuroendocrine tumors
- [Molecular Insight Pharmaceuticals, Inc. \(MIPI\) Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinica](#)
BioSpace: Oct 5 2009 6:23PM Matching: neuroendocrine tumors
- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical](#)

[Trial in Ne](#)

Genetic Engineering News: Oct 5 2009 4:56PM Matching: neuroendocrine tumors

- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical Trial in Ne](#)

Street Insider: Oct 5 2009 1:08PM Matching: neuroendocrine tumors

- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical Trial in Ne](#)

Yahoo! Canada: Oct 5 2009 12:53PM Matching: neuroendocrine tumors

- [Molecular Insight Pharmaceuticals Presents Azedra\(TM\) 12-Month Efficacy Data From Phase I Clinical Trial in Ne](#)

PR inside: Oct 5 2009 12:52PM Matching: neuroendocrine tumors

Neuroendocrine Tumors Clinical Trials:



- [Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors](#)

Neuroendocrine Tumors Patents:



- 7449554- [Antibodies against the PRO4977 polypeptides](#)
- 7488586- [PRO4409 polypeptides](#)
- 7488588- [Compounds related to or derived from GFR .alpha.4 and their use](#)
- 7488796- [PRO1269 polypeptides](#)
- 7491797- [PRO6308 polypeptide](#)
- 7495082- [Antibodies to PRO4349 polypeptides](#)
- 7495083- [PRO940 antibodies](#)
- 7504480- [PRO10275 polypeptides](#)
- 7507404- [Secreted and transmembrane polypeptides and nucleic acids encoding the same](#)
- 7507766- [Treatment of cancers](#)
- 7510700- [Pathological tissue detection and treatment employing targeted benzoindeole optical agents](#)
- 7485308- [26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor](#)
- 7482147- [Ubiquitin protease](#)
- 7479545- [PRO6001 antibodies](#)
- 7452551- [Targeted compositions for diagnostic and therapeutic use](#)
- 7452975- [Anti-PRO7168 antibodies](#)
- 7459155- [Treating abdominal pain due to pancreatitis with seaprose](#)
- 7459448- [Lactam compounds useful as protein kinase inhibitors](#)

- 7465785- [Polypeptide encoded by a nucleic acid over-expressed in melanoma](#)
- 7465786- [PRO1801 polypeptides](#)
- 7468363- [Methods for treatment of cancers using 3-\(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl\)-piperidine-2,6-dione](#)
- 7468424- [Secreted and transmembrane polypeptides and nucleic acids encoding the same](#)
- 7470667- [Methods of treating cancer using a modified endostatin protein](#)
- 7476721- [Modified cytokines for use in cancer therapy](#)
- 7517440- [Electrokinetic delivery systems, devices and methods](#)
- 7517890- [GTPase inhibitors and methods of use](#)
- 7569597- [Isoindoline compounds and methods of their use](#)
- 7569672- [Antibodies that bind to EphA2 and methods of use thereof](#)
- 7572284- [Method for automated localization of lesions in the gastrointestinal tract for treatment using laser light from an endorobot](#)
- 7572784- [Compounds and methods for inhibiting mitotic progression](#)
- 7572895- [Transferrin receptor antibodies](#)
- 7572896- [Antibodies to oncostatin M receptor](#)
- 7582293- [Anti-PRO6308 antibodies](#)
- 7589172- [PRO256 polypeptides](#)
- 7598341- [Molecules that selectively home to vasculature of premalignant or malignant lesions of the pancreas and other organs](#)
- 7598375- [Method of acylating maytansinol with chiral amino acids](#)
- 7566774- [PRO4977 polypeptides](#)
- 7563867- [PRO4356 polypeptides](#)
- 7560111- [HER2 antibody composition](#)
- 7521539- [Anti-PRO4989 antibodies](#)
- 7527791- [Humanized anti-TGF-beta antibodies](#)
- 7527969- [RAAG10 cell surface target and a family of antibodies recognizing that target](#)
- 7528235- [Multi-functional antibodies](#)
- 7534856- [PRO19624 antibodies](#)
- 7538086- [PRO1303 polypeptides](#)
- 7541018- [Treatment process using somatostatin analogues](#)
- 7550256- [Vimentin directed diagnostics and therapeutics for multidrug resistant neoplastic disease](#)
- 7553659- [CHD5 encoding nucleic acids, polypeptides, antibodies and methods of use thereof](#)
- 7557190- [Optimized proteins that target Ep-CAM](#)
- 7611879- [27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 molecules and uses therefor](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10
Copyright 1997-2009 - BioPortfolio Limited.

